Fox Run Management L.L.C. Grows Position in MoonLake Immunotherapeutics $MLTX

Fox Run Management L.L.C. raised its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 531.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,962 shares of the company’s stock after buying an additional 60,562 shares during the quarter. Fox Run Management L.L.C.’s holdings in MoonLake Immunotherapeutics were worth $948,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Alliancebernstein L.P. grew its holdings in shares of MoonLake Immunotherapeutics by 17.8% during the second quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after buying an additional 171,932 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $6,922,000. JPMorgan Chase & Co. grew its holdings in shares of MoonLake Immunotherapeutics by 381.0% during the fourth quarter. JPMorgan Chase & Co. now owns 837,739 shares of the company’s stock worth $11,041,000 after buying an additional 663,578 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of MoonLake Immunotherapeutics by 175.0% during the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after buying an additional 350,000 shares in the last quarter. Finally, Jefferies Financial Group Inc. grew its holdings in shares of MoonLake Immunotherapeutics by 1,900.0% during the fourth quarter. Jefferies Financial Group Inc. now owns 500,000 shares of the company’s stock worth $6,590,000 after buying an additional 475,000 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Insider Transactions at MoonLake Immunotherapeutics

In related news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total value of $62,962,500.00. Following the completion of the sale, the director owned 1,039,238 shares of the company’s stock, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 51,873 shares of the company’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $18.23, for a total transaction of $945,644.79. Following the completion of the sale, the chief executive officer directly owned 2,924,893 shares of the company’s stock, valued at $53,320,799.39. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,900,000 shares of company stock valued at $65,714,663 in the last three months. 12.02% of the stock is currently owned by insiders.

MoonLake Immunotherapeutics Trading Down 1.7%

Shares of MLTX opened at $17.49 on Thursday. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The firm has a 50-day moving average price of $17.76 and a 200 day moving average price of $16.39. The firm has a market capitalization of $1.29 billion, a P/E ratio of -4.52 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). Sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MLTX shares. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday. Zacks Research raised shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Oppenheimer upped their price objective on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $24.00 in a report on Monday, March 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Hold” and an average price target of $23.85.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.